Pega Pharmaceuticals-B (02565.HK) released its interim results, with research and development spending of 26.294 million yuan. It has successfully built a research and development pipeline matrix covering six drugs targeting chronic diseases.

The Smart Financial APP News reports that Pegasus BioPharmaceuticals-B (02565.HK) has released its interim performance for the six months ending on June 30, 2025. The group achieved other net income of RMB 178,000 (same unit), research and development expenses of RMB 26,294,000, and a loss per share of 0.25 yuan.